TrialNCT07361562
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
- Last update posted
- 09/04/2026
- Start
- 12/30/2025
- Sponsor
- Cogent Biosciences, Inc.
- Specialties
- oncology
Conditions: Advanced Solid Tumor, Adult; ERBB2 Altered Breast Cancer; ERBB2 Gene Amplification; HER2 Overexpression; Non-Small Cell Lung Cancer; HER2
Brief summary
This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpression.
Protocol documents and results are not hosted here. Verify every detail on ClinicalTrials.gov.